Abstract

Spinal cord injury (SCI) is a life-threatening condition that leads to permanent disability with partial or complete loss of motor, sensory, and autonomic functions. SCI is usually caused by initial mechanical insult, followed by a cascade of several neuroinflammation and structural changes. For ameliorating the neuroinflammatory cascades, MSC has been regarded as a therapeutic agent. The animal SCI research has demonstrated that MSC can be a valuable therapeutic agent with several growth factors and cytokines that may induce anti-inflammatory and regenerative effects. However, the therapeutic efficacy of MSCs in animal SCI models is inconsistent, and the optimal method of MSCs remains debatable. Moreover, there are several limitations to developing these therapeutic agents for humans. Therefore, identifying novel agents for regenerative medicine is necessary. Extracellular vesicles are a novel source for regenerative medicine; they possess nucleic acids, functional proteins, and bioactive lipids and perform various functions, including damaged tissue repair, immune response regulation, and reduction of inflammation. MSC-derived exosomes have advantages over MSCs, including small dimensions, low immunogenicity, and no need for additional procedures for culture expansion or delivery. Certain studies have demonstrated that MSC-derived extracellular vesicles (EVs), including exosomes, exhibit outstanding chondroprotective and anti-inflammatory effects. Therefore, we reviewed the principles and patho-mechanisms and summarized the research outcomes of MSCs and MSC-derived EVs for SCI, reported to date.

Highlights

  • Spinal cord injury (SCI) is a life-threatening, devastating injury to the spinal cord, leading to temporary or permanent changes to the cord, accompanied by partial or complete loss of motor, sensory, and autonomic functions [1,2]

  • These findings suggest that extracellular vesicles (EVs) possess many affirmative factors for the regeneration of injured spinal cords and, in the near future, may be a novel therapeutic agent for SCI in humans

  • Owing to the complex and long-term pathological process of SCI, recovery of the injured spinal cord is hampered by various factors

Read more

Summary

Introduction

Spinal cord injury (SCI) is a life-threatening, devastating injury to the spinal cord, leading to temporary or permanent changes to the cord, accompanied by partial or complete loss of motor, sensory, and autonomic functions [1,2]. Neuroinflammation is characterized by the activation of local resident immune cells, and this activation is arbitrated by a protein complex-inflammasome called the nucleotidebinding domain-like receptor protein 3 (NLRP3) inflammasome This inflammasome plays a very important role in SCI secondary injuries [78]. Animal experimental models have shown that the NLRP3 inflammasome may be triggered and up-regulated following SCI and that inhibition of the NLRP3 inflammasome promotes functional recovery after SCI [81–85] Both classic and alternative complement pathways in the local immune response can be activated after SCI [86]. It has recently been shown that reactive astrocytes eliminate red blood cells (RBCs) around SCI lesions through phagocytosis This mechanism, named the astrocytic erythrophagocytosis, is considered to contribute to the rapid removal of scattered RBCs around the injured site to prevent macrophage aggregation and associated destructive inflammation. Hu et al reported that miRNA-126 expression decreases after SCI, whereas increasing miRNA-126 levels appear to reduce inflammation and promote angiogenesis and functional recovery [106]

Mesenchymal Stem Cells for the Potential Treatment of Spinal Cord Injury
Bone Marrow Mesenchymal Stem Cells
Umbilical Cord-Derived Mesenchymal Stem Cells
Adipose-Derived Mesenchymal Stem Cells
Research Trials Using Extracellular Vesicles for Spinal Cord Injury
Conclusions and Future Perspectives

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.